Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

76.29USD
7:17pm BST
Change (% chg)

$0.78 (+1.03%)
Prev Close
$75.51
Open
$74.53
Day's High
$76.65
Day's Low
$74.49
Volume
72,574
Avg. Vol
129,239
52-wk High
$99.77
52-wk Low
$51.66

Latest Key Developments (Source: Significant Developments)

Agios Pharmaceuticals - Co, Celgene Agreed To Terminate Collaboration, License Deal
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC - ON SEPT 4, CO, CELGENE AGREED TO TERMINATE COLLABORATION AND LICENSE DEAL DATED APRIL 27, 2015 BETWEEN CO AND CELGENE.AGIOS PHARMA- FOR SPECIFIED PERIOD CELGENE SHALL BE PROHIBITED FROM DEVELOPING, COMMERCIALIZING PRODUCT THAT INHIBITS ISOCITRATE DEHYDROGENASE 1.AGIOS - ON SEPT 4, CO, CELGENE ALSO AGREED TO TERMINATE LICENSE AGREEMENT DATED APRIL 27, 2015 BETWEEN CO'S UNIT AND CELGENE INTERNATIONAL II SARL.AGIOS PHARMACEUTICALS INC - PROHIBITED PRODUCTS APPLY FOR INHIBITS ISOCITRATE DEHYDROGENASE 1 AT SPECIFIED LEVELS OF BINDING FOR ANY INDICATION.AGIOS PHARMACEUTICALS INC - COMPANY SHALL BE PROHIBITED FROM DEVELOPING, MANUFACTURING OR COMMERCIALIZING AG-881 IN HEMATOLOGIC INDICATIONS.AGIOS PHARMACEUTICALS - FROM & AFTER AG-881 AGREEMENT TERMINATION DATE, CO TO OBTAIN SOLE GLOBAL RIGHTS TO AG-881 - SEC FILING.AGIOS PHARMACEUTICALS - NO PARTY TO HAVE FINANCIAL OBLIGATION TO OTHER PARTIES, INCLUDING MILESTONES, ROYALTIES, OTHER PAYMENTS AFTER TERMINATION DATE.  Full Article

Agios Announces Chief Executive Officer Succession Plan
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES CHIEF EXECUTIVE OFFICER SUCCESSION PLAN.AGIOS PHARMACEUTICALS SAYS CURRENT CEO DAVID SCHENKEIN TO BECOME EXECUTIVE CHAIRMAN, EFFECTIVE FEB 1, 2019.AGIOS PHARMACEUTICALS SAYS JACQUALYN FOUSE TO SUCCEED SCHENKEIN AS CEO; FOUSE WILL REMAIN MEMBER OF BOARD.AGIOS PHARMACEUTICALS SAYS CURRENT CHAIRMAN JOHN MARAGANORE WILL TRANSITION TO DIRECTOR OF BOARD, EFFECTIVE FEB 1, 2019.  Full Article

Agios Q2 Revenue $40.4 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $40.4 MILLION.Q2 REVENUE VIEW $11.3 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $1.19.  Full Article

FDA Says Tibsovo's Prescribing Information Includes Boxed Warning Regarding Differentiation Syndrome
Friday, 20 Jul 2018 

July 20 (Reuters) - U.S. Food and Drug Administration::FDA SAYS TIBSOVO'S PRESCRIBING INFORMATION INCLUDES BOXED WARNING THAT A POTENTIALLY FATAL ADVERSE REACTION KNOWN AS DIFFERENTIATION SYNDROME CAN OCCUR.  Full Article

Agios Pharmaceuticals Says FDA Grants Approval Of Tibsovo
Friday, 20 Jul 2018 

July 20 (Reuters) - Agios Pharmaceuticals Inc ::FDA GRANTS APPROVAL OF TIBSOVO®, THE FIRST ORAL, TARGETED THERAPY FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND AN IDH1 MUTATION.AGIOS PHARMACEUTICALS - TIBSOVO, AN ORAL, TARGETED INHIBITOR OF IDH1 ENZYME, IS FIRST FDA-APPROVED THERAPY FOR PATIENTS WITH R/R AML & AN IDH1 MUTATION.  Full Article

Agios Announces Proposed Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING.SAYS ALL OF SHARES IN OFFERING ARE TO BE SOLD BY AGIOS.  Full Article

Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE.AGIOS PHARMACEUTICALS INC - SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES EXPECTED IN 4Q 2018.AGIOS - 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019.AGIOS PHARMACEUTICALS INC - TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018.AGIOS PHARMACEUTICALS INC - PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018.AGIOS PHARMACEUTICALS INC - MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018.  Full Article

Agios Submits New Drug Application To The FDA For Ivosidenib
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION.AGIOS PHARMACEUTICALS INC - EXPECTS TO INITIATE PHASE 1 TRIAL FOR AG-270 IN Q1 OF 2018.AGIOS PHARMACEUTICALS INC - ‍ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AG-270 TARGETING MTAP-DELETED TUMORS​.  Full Article

Agios Pharmaceuticals Files For Potential Mixed Shelf Offering
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Agios presents updated phase 1 data from dose expansion cohort of ivosidenib
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Agios Pharmaceuticals Inc :Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma.Agios Pharmaceuticals Inc - ‍ivosidenib well-tolerated in patients with low grade glioma​.Agios Pharmaceuticals Inc - ‍additional preclinical data demonstrate that ivosidenib and AG-881 suppress 2-HG levels in brain tumor mouse models​.Agios Pharmaceuticals Inc - ‍there were 5 patients with serious adverse events (SAE) and all were deemed unrelated to study treatment​.Agios Pharmaceuticals - ‍preliminary data suggest that both molecules suppress oncometabolite D-2-hydroxyglutarate in an orthotopic brain tumor model​.Agios Pharmaceuticals - study ‍to refine imaging methodology, assess biological effects of IDH inhibitors in perioperative study planned for H1 of 2018​.  Full Article

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.